SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lasa Supergenerics - Quaterly Results

14 Feb 2026 Evaluate
The Sales for the quarter ended December 2025 of Rs. 21.99 million declined by -93.35% from Rs. 330.80 millions.The Net Loss for the quarter ended December 2025 is Rs. -25.56 millions as compared to Net Profit of Rs. 54.94 millions of corresponding quarter ended December 2024Operating profit Margin for the quarter ended December 2025 slipped to -7.31% as compared to 9.33% of corresponding quarter ended December 2024


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202512 202412 % Var 202512 202412 % Var 202503 202403 % Var
Sales 21.99 330.80 -93.35 252.72 1033.11 -75.54 1424.48 1043.35 36.53
Other Income 0.18 6.69 -97.31 1.59 26.21 -93.93 50.12 1.02 4813.73
PBIDT -7.31 9.33 -178.35 -50.91 54.74 -193.00 112.77 22.64 398.10
Interest 1.12 4.72 -76.27 2.58 25.85 -90.02 26.92 19.32 39.34
PBDT -8.43 87.06 -109.68 -259.24 111.34 -332.84 -70.84 -84.41 -16.08
Depreciation 15.70 27.96 -43.85 47.10 84.01 -43.94 123.00 106.73 15.24
PBT -24.13 59.10 -140.83 -306.34 27.33 -1220.89 -193.84 -191.14 1.41
TAX 1.43 4.16 -65.63 -7.05 31.99 -122.04 -46.26 26.18 -276.70
Deferred Tax 1.43 4.16 -65.63 -7.05 31.99 -122.04 -46.26 26.18 -276.70
PAT -25.56 54.94 -146.52 -299.29 -4.66 6322.53 -147.58 -217.32 -32.09
Equity 501.01 501.01 0.00 501.01 501.01 0.00 501.01 501.01 0.00
PBIDTM(%) -33.24 2.82 -1278.64 -20.14 5.30 -480.19 7.92 2.17 264.84

Lasa Supergenerics Share Price

7.89 0.29 (3.82%)
15-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1696.65
Dr. Reddys Lab 1218.30
Cipla 1226.65
Zydus Lifesciences 936.00
Lupin 2339.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×